Anifrolumab and risk of cancers and serious infections in SLE
Official title: A Non-Interventional Multi-Country Post-Authorisation Safety Study (PASS) to Assess the Incidence of Serious Infections & Malignancies in Systemic Lupus Erythematosus (SLE) Patients Exposed to Anifrolumab
Run by AstraZeneca · NCT07000110 · Data updated 2026-11-12
This project will see if adults with moderate-to-severe SLE who start anifrolumab have different rates of cancers and serious infections than similar patients receiving standard care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 130 Years |
| Sex | All |
| Enrollment | 3506 (estimated) |
| Sponsor | AstraZeneca Industry-sponsored |
| Drugs / interventions | anifrolumab |
| Locations | 4 sites (Copenhagen and 3 other locations) |
| Status | Recruiting |
| Started | January 26, 2026 |
| Main results expected | November 30, 2031 |
| Study ends | November 30, 2031 |
| Registry record updated | September 16, 2026 |
| Trial ID | NCT07000110 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with moderate-to-severe SLE who experienced at least one flare in the prior six months, who are starting anifrolumab as their first dose during the study period, and who have at least 12 months of prior medical data are the intended participants.
✕Probably not a fit
People with prior malignancy, HIV/AIDS or congenital immunodeficiency, prior organ or bone marrow transplant, recent serious infection, or those under 18 or not starting anifrolumab would not meet the criteria and are unlikely to benefit from this study's findings directly.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multi-site observational cohort comparison that uses the date of first anifrolumab prescription as an index date to follow patients for malignancies and serious infections. Eligible patients are adults with moderate-to-severe SLE who had at least one flare in the six months before the index date and at least 12 months of prior data, and patients with prior malignancy, HIV/immunodeficiency, transplant, or recent serious infection are excluded. The study compares event rates between those initiating anifrolumab and a matched group receiving standard of care, with statistical adjustment for baseline differences. Data will be drawn from participating European sites and analyzed to estimate relative safety risks in real-world use.
Why it matters
Potential benefit: If successful, the results could clarify real-world safety risks of anifrolumab and help patients and clinicians make more informed treatment decisions.
How similar studies have gone: Clinical trials and observational safety studies of anifrolumab and other biologics have identified infection risks and provided useful safety signals, but large real-world comparative data specifically on malignancy risk remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * First prescription of anifrolumab in the study period (no anifrolumab prescription prior to index date): date of first anifrolumab prescription will be the index date * A minimum data availability of 12 months prior to index date * Age ≥18 years at index date * SLE severity: patients with moderate to severe SLE at index date * SLE activity: patients with at least a flare (uncontrolled SLE) in the 6 months prior to index date Exclusion Criteria: * A diagnosis of any malignancy prior to index date * A diagnosis of HIV/AIDS or congenital immunodeficiency prior to index date * Organ or bone marrow transplant procedure prior to index date * A diagnosis of serious infection in the previous 6 months
Where it's running
-
Research Site
Copenhagen, Denmark Recruiting -
Research Site
Charenton-le-Pont, France Recruiting -
Research Site
Essen, Germany Recruiting -
Research Site
Barcelona, Spain Recruiting
Study contacts
- Study coordinator: AstraZeneca Clinical Study Information Center
- Email: information.center@astrazeneca.com
- Phone: 1-877-240-9479
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of anifrolumab on arterial inflammation in SLE patients
This study tests whether anifrolumab can reduce blood vessel inflammation in people with active systemic lupus erythematosus.
-
Subcutaneous anifrolumab in children with systemic lupus erythematosus
This study tests whether subcutaneous anifrolumab is safe and how it behaves in the body for kids with moderate to severe SLE already on standard care.
-
Weekly subcutaneous anifrolumab added to antimalarial for people with lupus who are immunosuppressant- and biologic-naïve
This trial tests whether once-weekly 120 mg subcutaneous anifrolumab plus antimalarial (with or without steroids) helps adults with lupus who have not used immunosuppressants or biologics reach remission and come off long-term steroids.
-
Real-world use of anifrolumab for active systemic lupus erythematosus
This project will see if anifrolumab helps adults with active systemic lupus erythematosus when given in routine clinical care.
-
Anifrolumab Pregnancy Study in women with lupus
This study looks at pregnancy outcomes in women with moderate to severe SLE who took anifrolumab during pregnancy and compares them to similar women who did not take the drug.
-
Monitoring pregnancy and infant outcomes after anifrolumab exposure
This program collects health information to see if exposure to the lupus medicine anifrolumab affects pregnant people or their babies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.